StockpollyBeta
Get App
Popularity #1,333
ELVN · NASDAQ · Biotechnology

Enliven Therapeutics (ELVN)

Develops small-molecule therapies centered on ELVN-001 for chronic myeloid leukemia.

$46.10
vs last close−2.09 (−4.33%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
242326252727322925342837
Research & development201820192121252118212129
3566667771378
General & administrative3566667771378
Other expenses100000000000
Operating income−24−23−26−25−27−27−32−29−25−34−28−37
333544335545
Interest income333444335545
Other non-operating income0−3−3−5−4−4−3−3−5−5−4−5
Income before tax−21−19−23−20−23−23−29−25−20−30−24−32
Income tax expense000000000000
Net income from continuing operations−21−19−23−20−23−23−29−25−20−30−24−32
Net income−21−19−23−20−23−23−29−25−20−30−24−32
EPS, basic−$0.51−$0.47−$0.54−$0.41−$0.48−$0.46−$0.57−$0.49−$0.32−$0.45−$0.38−$0.49
EPS, diluted−$0.51−$0.47−$0.54−$0.41−$0.48−$0.46−$0.57−$0.49−$0.32−$0.45−$0.38−$0.49
Weighted average shares, basic414142484850505262576366
Weighted average shares, diluted414142484850505262576366
EBITDA−24−19−23−20−23−23−28−25−20−30−24−32
Depreciation & amortization000000000000
EBIT−24−19−23−20−23−23−29−25−20−30−24−32